These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28819801)

  • 1. Botulinum Toxin Treatment in Multiple Sclerosis-a Review.
    Safarpour Y; Mousavi T; Jabbari B
    Curr Treat Options Neurol; 2017 Aug; 19(10):33. PubMed ID: 28819801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessment: Botulinum neurotoxin in the treatment of autonomic disorders and pain (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
    Naumann M; So Y; Argoff CE; Childers MK; Dykstra DD; Gronseth GS; Jabbari B; Kaufmann HC; Schurch B; Silberstein SD; Simpson DM;
    Neurology; 2008 May; 70(19):1707-14. PubMed ID: 18458231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence-based review and assessment of botulinum neurotoxin for the treatment of urologic conditions.
    Chancellor MB; Elovic E; Esquenazi A; Naumann M; Segal KR; Schiavo G; Smith CP; Ward AB
    Toxicon; 2013 Jun; 67():129-40. PubMed ID: 23415704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the impact on health-related quality of life of repeated detrusor injections of botulinum toxin in patients with idiopathic or neurogenic detrusor overactivity.
    Gamé X; Khan S; Panicker JN; Kalsi V; Dalton C; Elneil S; Hamid R; Dasgupta P; Fowler CJ
    BJU Int; 2011 Jun; 107(11):1786-92. PubMed ID: 21040367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. More Than 15 Years of Experience with Intradetrusor OnabotulinumtoxinA Injections for Treating Refractory Neurogenic Detrusor Overactivity: Lessons to Be Learned.
    Leitner L; Guggenbühl-Roy S; Knüpfer SC; Walter M; Schneider MP; Tornic J; Sammer U; Mehnert U; Kessler TM
    Eur Urol; 2016 Sep; 70(3):522-8. PubMed ID: 27106070
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intradetrusorial Botulinum Toxin in Patients with Multiple Sclerosis: A Neurophysiological Study.
    Conte A; Giannantoni A; Gubbiotti M; Pontecorvo S; Millefiorini E; Francia A; Porena M; Berardelli A
    Toxins (Basel); 2015 Aug; 7(9):3424-35. PubMed ID: 26343721
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Botulinum Toxin A in the Treatment of Lower Urinary Tract Disorders: A Review of the Literature.
    Moore DC; Cohn JA; Dmochowski RR
    Toxins (Basel); 2016 Mar; 8(4):88. PubMed ID: 27023601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin A for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients.
    Deffontaines-Rufin S; Weil M; Verollet D; Peyrat L; Amarenco G
    Int Braz J Urol; 2011; 37(5):642-8. PubMed ID: 22099277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection.
    Liu HT; Chancellor MB; Kuo HC
    Eur Urol; 2009 Oct; 56(4):700-6. PubMed ID: 18472208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Has botulinum toxin therapy come of age: what do we know, what do we need to know, and should we use it?
    da Silva CM; Cruz F
    Curr Opin Urol; 2009 Jul; 19(4):347-52. PubMed ID: 19444121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Do we understand how botulinum toxin works and have we optimized the way it is administered to the bladder? ICI-RS 2014.
    Apostolidis A; Rahnama'i MS; Fry C; Dmochowski R; Sahai A
    Neurourol Urodyn; 2016 Feb; 35(2):293-8. PubMed ID: 26872570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Botulinum toxin for the management of bladder dysfunction.
    Schurch B
    Drugs; 2006; 66(10):1301-18. PubMed ID: 16903766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin in urology: a review of clinical potential in the treatment of urologic and sexual conditions.
    Chung E
    Expert Opin Biol Ther; 2015 Jan; 15(1):95-102. PubMed ID: 25347039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder.
    Chen SF; Chang CH; Kuo HC
    Toxins (Basel); 2016 May; 8(6):. PubMed ID: 27249005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence-based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome.
    Esquenazi A; Albanese A; Chancellor MB; Elovic E; Segal KR; Simpson DM; Smith CP; Ward AB
    Toxicon; 2013 Jun; 67():115-28. PubMed ID: 23220492
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Botulinum Toxin for Neuropathic Pain: A Review of the Literature.
    Oh HM; Chung ME
    Toxins (Basel); 2015 Aug; 7(8):3127-54. PubMed ID: 26287242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity.
    Conte A; Giannantoni A; Proietti S; Giovannozzi S; Fabbrini G; Rossi A; Porena M; Berardelli A
    Eur J Neurol; 2012 May; 19(5):725-32. PubMed ID: 22212295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Botulinum toxin treatment of hip adductor spasticity in multiple sclerosis].
    Wissel J; Entner T
    Wien Klin Wochenschr; 2001; 113 Suppl 4():20-4. PubMed ID: 15506048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of intravesical botulinum toxin-A injections in women with idiopathic overactive bladder symptoms.
    Marcelissen TA; Rahnama'i MS; Snijkers A; Schurch B; De Vries P
    World J Urol; 2017 Feb; 35(2):307-311. PubMed ID: 27272312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and potential urological applications of botulinum toxin A.
    Jiang YH; Liao CH; Kuo HC
    Nat Rev Urol; 2015 Sep; 12(9):519-33. PubMed ID: 26260879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.